<DOC>
	<DOCNO>NCT00189930</DOCNO>
	<brief_summary>The objective study compare two dos MVA-nef vs. MVA-BN induce Nef-specific cellular immune response HIV-1 infect patient</brief_summary>
	<brief_title>An Evaluation Immunogenicity Safety Two Doses MVA-nef vs. MVA-BN HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Ages 1860 HIV1 infection , document licensed PCR kit ELISA ( confirm complementary assay e.g . Western blot HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA ) time prior study entry . Stable HAART least 6 consecutive month prior study entry ( change one drug another drug due reason virologic failure allow ) Plasma HIV1 RNA level &lt; 50 copies/ml least 6 month prior study entry ( two single blip 200 HIV1 RNA copies/ml acceptable resolve spontaneously without change HAART ) Plasma HIV1 RNA level &lt; 50 copies/ml study entry CD4 nadir &gt; 100 CD4+ cell count &gt; 250/µl ( one measurement within 4 month prior study entry one measurement within screen phase ) For woman , negative serum pregnancy test screen negative urine serum pregnancy test within 24 hour prior vaccination . If volunteer female childbearing potential , agree use acceptable method contraception , become pregnant least 56 day last vaccination . A woman consider childbearing potential unless postmenopausal surgically sterilize . ( Acceptable contraception method restrict intrauterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive jelly , cream foam ; Norplant® DepoProvera® ) use method minimum 30 day prior vaccination ) . ALT/SGPT , AST/SGOT , alkaline phosphatase &lt; 3 time institutional upper limit normal ( ULN ) . Urine protein dipstick urinalysis &lt; 100mg/dl &lt; 2+ proteinuria CBC : Haemoglobin &gt; 8 g/dl ; White blood cell great 2,500 less 11,000/mm3 ; Platelets great equal 100,000/mm3 Read , sign date informed consent document advise risk benefit study language able understand , prior performance study specific procedure Cardiac enzymes : within normal range . Pregnant breastfeed woman . Administration HIV nef vaccine vaccinia immunization within past 5 year . Uncontrolled serious infection i.e . respond antimicrobial therapy . History serious medical condition , opinion investigator would compromise safety subject . History active autoimmune disease . Persons vitiligo thyroid disease thyroid replacement exclude . History malignancy , squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . History clinical manifestation clinically significant mental illness haematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder . Any condition might interfere study objective would limit subject 's ability complete study opinion investigator . ECG clinical significance ( complete left right bundle branch block , sustain ventricular arrythmia , 2 PVCs row , ST elevation consistent ischemia ) . History myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , heart condition care doctor . 3 follow risk factor : 1 . High blood pressure require therapy . 2 . High blood cholesterol ( &gt; 300 mg/dl ratio LDL/HDL ≥ 3 ) induce HIV therapy . 3 . Diabetes mellitus high blood sugar . 4 . He/she first degree relative ( example mother , father , brother , sister ) heart condition age 50 . 5 . Smoking cigarette . History chronic alcohol abuse ( 40g / day least 6 month ) and/or intravenous drug abuse ( within past 6 month ) . History allergic disease reaction likely exacerbate component vaccine . History anaphylaxis severe allergic reaction . Acute disease ( moderate severe illness without fever ) time enrolment . Any vaccination active vaccine within period start 30 day prior administration vaccine end 30 day administration study vaccine . Any vaccination inactive vaccine within period start 14 day prior administration vaccine end 14 day administration study vaccine . Chronic administration ( defined 14 day ) immuno suppressant immunemodifying drug study period ( Corticosteroid nasal spray permissible . Subjects use topical inhaled steroid enrol therapy complete ) . Administration plan administration immunoglobulin and/or blood product period start 3 month prior administration vaccine end study conclusion . Use investigational nonregistered drug vaccine study vaccine within 30 day 7 halflives ( whichever longer ) precede first dose study vaccine , plan administration drug study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>